Mills & Reeve Annual Life Sciences Conference

Sep
22
2026

Date: September 22, 2026

Location: London, UK

Mintz is pleased to participate in the upcoming Mills & Reeve Annual Life Sciences Conference in London on September 22. Members Joanne Hawana and Tali Tuchin will be featured as panelists.

Joanne will speak on the panel, "Global Outlook: Current Regulatory Landscape and What's Ahead." The session will explore current and emerging regulatory developments impacting the life sciences industry across the United States and Europe. Joanne will join fellow panelists from Kinstellar and Mills & Reeve to provide an international perspective on the evolving regulatory landscape.

Tali will join James Fry of Mills & Reeve for the panel "Licensing and Partnering: Avoiding the Pitfalls That Slow Deals Down." The discussion will examine trends shaping cross-border partnering and licensing activity across the United States and Europe, as well as the factors that commonly delay transactions, including due diligence, internal governance, and strategic misalignment. Attendees will gain practical insights into anticipating challenges and helping transactions progress more efficiently from initial discussions to successful partnerships.

Professionals

  • Joanne S. Hawana
  • Tali M. Tuchin

    • Related Practices

  • Licensing & Collaborations
  • FDA Regulatory

    • Related Industries

  • Life Sciences
  • Health Care

    • Speakers

    Joanne S. Hawana

    Joanne S. Hawana

    Panelist

    Joanne S. Hawana is a Member at Mintz who counsels global clients on the regulatory and distribution-related implications when bringing a new FDA-regulated product to market and how to ensure continued compliance after a product is commercialized.
    Tali M. Tuchin

    Tali M. Tuchin

    Speaker

    Tali M. Tuchin is a Mintz Member who handles complex business and technology transactions, including patent licenses and assignments, research and development agreements, and collaboration agreements. Her clients range from start-ups to large public companies in a variety of sectors, including biotechnology, pharmaceuticals, diagnostics, medical devices, health care, energy, and technology.